PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

<p>PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced today that on December 4, 2023, PDS Biotech granted nonstatutory stock options to Lars Boesgaard, the Company’s new Chief Financial Officer, [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/pds-biotechnology-reports-inducement-grant-under-nasdaq-listing-rule-5635c4/">PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>